Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 14, 2018JCO Precision Oncology

Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations

View Full Paper
Ask AI
Bookmark
Share

Authors

BCBenedito A. CarneiroBrown UniversityKCKatharine A. CollierThe Ohio State UniversityRNRebecca J. NagyNipissing University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Carneiro et al. (2018) studied this question.

synapsesocial.com/papers/6a73eba36acfb9d2a78dee86https://doi.org/10.1200/po.17.00176
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA2015 · 724 citations
  2. 2Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer2015 · 414 citations
  3. 3Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas2011 · 584 citations
  4. 4Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors2017 · 277 citations